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ABSTRACT
Purpose. To compare the efficacy of autologous 
chondrocyte transplantation (ACT) versus non-
operative measures for cartilage repair in rabbits.
Methods. Nine New Zealand white rabbits were 
used. Identical focal defects were created in the 
articular cartilage of both knees. One month later, 
the right knee was repaired via ACT, while the left 
knee was left untreated (control group). The quality 
of cartilage tissues in both knees was compared 3 
months later, according to the quantitative analysis 
of glycosaminoglycan (GAG) in the cartilage and 
macroscopic examination of histology using the 
Brittberg/International Cartilage Research Society 
(ICRS) score.
Results. Microscopic examination showed enhanced 
regeneration following ACT repair. Quantification 
analysis revealed significantly higher cellular 
expression of GAG in the ACT-treated knees (1.12 
vs 0.81 μg GAGs/mg protein, p=0.008). The mean 
Brittberg/ICRS score was significantly higher in the 
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treated knees (6.00 vs 1.89, p=0.007).
Conclusion. ACT is superior to non-operative 
measures for repairing focal cartilage defects, 
as determined by favourable histological and 
immunohistological outcomes at the cellular level.
Key words: cartilage; chondrocytes; tissue engineering; 
transplantation, autologous
INTRODUCTION
Regeneration of cartilage is poor because of the 
absence of neurovascular supply,1–8 and hence 
surgical repair following injury is difficult, and 
outcomes vary.2–5,9 Tissue-engineering modalities 
offer biological therapies for cartilage regeneration.6–10 
Autologous chondrocyte transplantation (ACT) is a 3-
stage procedure with good long-term durability and 
outcomes.7 Only a few hospitals offer this modality 
as a standard practice,11–13 because it is expensive (in 
terms of cell preparation), technically demanding, and 
yields similar results to other techniques requiring 
less expertise.7–14
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 The efficacy of ACT is controversial because most 
assessments are based on patient outcome scores 
and investigators’ own visual assessment and hence 
are prone to bias.12–20 Our study was more objective 
because regeneration of cartilage tissues was analysed 
both quantitatively and qualitatively.
MATERIALS AND METHODS
Nine male New Zealand white rabbits aged 6 to 7 
months weighing 2.5 kg were used. All were reared 
at the animal research facility of our university. 
The protocol was approved by the animal ethics 
committee. All surgical procedures were performed 
under general and local anaesthesia using aseptic 
techniques. No preoperative antibiotics were 
administered.
 Both knee joints were opened via a medial 
para-patellar approach along the patellar tendon 
(Fig. 1a). A piece of cartilage (5 mm in diameter 
and 2 mm in depth) was biopsied from the medial 
femoral condyle using a custom-made cylindrical 
chondrotome (Fig. 1b). A defect was created using a 
scalpel until subchondral bone was reached (Fig. 1c), 
mimicking a clinical situation of delayed presentation 
and a full-thickness tear. The wound was closed 
and postoperative analgesia was administered for 2 
days.
 The harvested cartilages were sent for cell 
culture. They were finely chopped and digested in 
an incubator for 24 hours. The chondrocytes attained 
were passaged and propagated using Ham’s F-12 
and DMEM media. No scaffolding or enhancers were 
used.
 One month later, the right knee was re-opened via 
the previous incision scar, and cultured chondrocytes 
were implanted. Tight opposition at the edges of 
the periosteal flap was achieved using microsutures 
and fibrin glue. Three dosages of antibiotics were 
administered following surgery.
 There was no wound infection or contamination of 
cell cultures. The rabbits were allowed to move freely 
within their cages and were killed 3 months later. The 
knees were evaluated macroscopically based on the 
Brittberg/International Cartilage Research Society 
(ICRS) score1,2,9 for cartilage repair by an independent 
observer. The distal femurs were harvested, weighed, 
and measured.
 Half of the specimens were used for histological 
examination and immunohistochemical staining. They 
were fixed in 10% phosphate-buffered formalin (4% 
formaldehyde) for at least 24 hours, then decalcified 
and embedded in paraffin, and eventually sectioned 
into 5 μm thick slices on slides, deparafinised in 
xylene, and transferred in aqua dest with decreasing 
concentrations of ethanol. Slides were stained with 
haematoxylin and eosin (H&E) and Safranin-O.
 Synthesis of type-II collagen was verified 
using immunohistochemical staining. Sections 
were treated with protease enzyme for about 10 
minutes and washed with Tris-buffered saline prior 
to incubation with type-II primary antibody or 
phosphate-buffered saline alone (as the negative 
control) for 1 hour. Specimens were then incubated 
with horseradish peroxidase enzyme conjugated 
Figure 2 One month later, the defect in the right knee was 
covered with a periosteal flap (arrow).
Figure 1 Creation of a defect in both knees using a customised 
chondrotome (arrow).
(a) (b)
(c) (d)
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goat-anti-mouse secondary antibody for 30 minutes 
prior to visualisation using the chromogen substrate 
diaminobenzidine. Stained slides were then mounted 
in dibutyl polystyrene xylene.
 The other half of the specimens were used for 
biochemical assay of glycosaminoglycan (GAG) 
using the Blyscan Glycosaminoglycan Assay Kit 
(Biocolor, UK). GAG is a major component of the 
articular cartilage. Specimens were finely dissected 
and then digested using radioimmunoprecipitation 
buffer supplemented with protease inhibitor for 
1 hour. Aliquots of each sample were mixed with 
dimethylmethylene blue dye and reagents from 
the GAG assay kit. The absorbance at 656 nm was 
measured on the spectrophotometer and compared 
to a plot of standards made from shark chondroitin 
sulphate to determine GAG content. GAG 
quantification indicates cellular expression of the 
chondrocytes within the matrix and is an indicator of 
tissue repair.
 The GAG values complement the Brittberg/
ICRS scores. The Brittberg/ICRS scores and GAG 
contents between the treated and control groups 
were compared using the Wilcoxon signed-rank 
test. A p value of <0.01 was considered statistically 
significant.
RESULTS
No obvious differences in the limp between the 2 
sides was noted after the first procedure. The limp 
was more notable in the left knee after the second 
procedure, but the gait became normal at the end of 
the second week. On gross examination, the defect 
in the treated knees showed good filling with a 
smooth surface (Fig. 3a), with no obvious periosteal 
thickening. Repairs were mainly of hyaline cartilage 
with good ingrowth. Only one specimen showed 
scraping on the medial tibial articular surface. In the 
control knees, partial filling with an irregular surface 
was seen (Fig. 3b), with scraping on the articular 
surface of all tibial plateaus. Repairs were mainly of 
fibrous or fibrocartilaginous tissue.
 Using Safranin-O staining, tissues in the 
treated knees were heavily stained indicating good 
proteoglycan expressions within the matrix, but the 
stain was poor and uneven in the control knees (Fig. 
4). Using H&E staining, chondrocytes in the treated 
knees were abundant with good-quality surrounding 
tissue similar to normal cartilage. In the control knees, 
no obvious repairs or cells were noticeable (Fig. 5).
 Using immunohistochemical staining, the treated 
knees showed homogeneous distribution of type-II 
collagen similar to the surrounding normal cartilage. 
In the control knees, no cartilage filling was noted; 
only some type-II collagen was seen at the base and 
border of the defects (Fig. 6).
(a) (b)
Figure 3 Gross appearance of the (a) right knee with a 
completely filled defect and (b) left knee with an irregular 
surface.
(a) (b) (c)
Figure 4 (a) Moderate-to-good cartilage growth with adequate smooth surface is seen in the right knees after 2 months; (b) no repair 
and only fibrous and fibrocartilaginous tissues are seen in the left knees. (c) A healthy cartilage is thick and even, with a smooth surface 
and well-distributed chondrocytes (Safranin-O, x40).
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 In the right and left knees respectively, the 
mean GAGs were 1.12 and 0.81 μg GAGs/mg 
protein (p=0.008), whereas the mean Brittberg/ICRS 
scores were 6.00 and 1.89 (p=0.007) [Table]. ACT is 
superior to non-operative measures in repairing focal 
cartilage defects, with favourable histological and 
immunohistological outcomes at the cellular levels.
DISCUSSION
Articular cartilage consists of an extracellular matrix 
(mainly type-II collagen) and a cellular component 
(chondrocytes). The collagen is embedded in a firm, 
hydrated gel of proteoglycans. GAG is a component 
of proteoglycans and hyaluronic acid and helps 
Treated site
(a)
Border to the 
defect
(b)
Figure 5 (a) Good filling with viable cells in the matrix of the 
repair site (H&E, x40). (b) The defect site remains unfilled. The 
subchondral bone is exposed (H&E, x40).
Border of the 
treated site
Treated site
Normal 
cartilage
(a)
Normal 
cartilage
Untreated site
(b)
Figure 6 (a) Abundant type-II collagen is seen in the treated 
knees (immunohistochemical staining, x100). (b) Type-II collagen 
is only seen at the bottom and border of the defect (arrows) 
[immunohistochemical staining, x40].
Parameter Knee p Value (Wilcoxon signed-rank test)
Left Right
Mean (SD) GAG (µg GAG/g protein) 0.81 (0.17) 1.12 (0.48) 0.008
Mean (SD) Brittberg/ICRS score 1.89 (1.54) 6.00 (1.23) 0.007
Table
Mean glycosaminoglycan (GAG) and Brittberg/International Cartilage Research Society (ICRS) scores for the right and 
left knees
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maintain tissue homoeostasis.12,13 It repels water and 
prevents disintegration of matrix materials during 
injury,21,22 absorbs shock, and lubricates the synovial 
joint.
 GAG and type-II collagen were heavily expressed 
in the treated but not the control knees (except at the 
base and border of the defects).7,16,21,22 A ‘bioactive 
chamber theory’2,17–19 postulates that new cartilage 
may originate from normal cartilage surrounding the 
defect, calcified zones, chondrocytes in the cryptae of 
the irregular subchondral bone, bone marrow of the 
osteochondral defect, or synovial fluid. Cells in the 
adjacent cartilage show mitotic activity after injury, 
but not sufficient for any noticeable repair. Therefore, 
patients may attain partial symptomatic relief despite 
no treatment. This may lead to delay in treatment 
and further cartilage damage (even in the opposite 
articular surface).
 The transplanted chondrocytes can remain viable 
for a long time.23–26 They can be traced using radio-
isotope cell labelling or fluorescence cell labelling and 
visualised using fluorescent or confocal microscopy 
or polymerase chain reaction. A mean of 87% of 
cell viability is maintained for up to 4 weeks; only 
14% of the one million chondrocytes transplanted 
remained, but the total numbers of cells increase with 
time. This suggests that ACT keeps the transplanted 
chondrocytes viable and promotes cell migration from 
the surrounding tissues.23–25 Nonetheless, the source 
and fate of these cells were not determined. They 
may migrate into the surrounding tissues, participate 
in cell-mediated immune death or even in apoptosis. 
Long-term survival of transplanted chondrocytes 
is difficult to follow because of (1) degradation of 
fluorescent dyes and (2) chondrocytes losing tagged 
dyes in their progeny when undergoing in vivo 
proliferation/differentiation.27
 ACT is preferred over subchondral drilling and 
mosaicplasty as a treatment of choice,13 but the high 
cost incurred does not justify its use in standard 
practice. Subchondral drilling creates channels 
connecting marrow into the defects and enables 
mesenchymal-cell migration and differentiation into 
mature chondrocytes to promote cartilage repair. 
However, it has not been useful or beneficial,15,22,28 
because (1) the defects are repaired by callus 
formation resulting in stiffer cartilage and trauma 
to the opposite articular surface2; (2) breaching the 
subchondral bone may disturb the elastic resilience 
equilibrium of cartilage and subchondral bone 
functioning as a shock absorber; when under high 
loads, both the cartilage and subchondral bone may 
deform resulting in a global deformity of the articular 
architecture29,30; (3) type-I collagen and fibrous (and 
fibrocartilage) materials filling in the defect may 
damage the surrounding cartilage structure.
 Mosaicplasty uses osteochondral plugs obtained 
from the non–weight bearing portion of the articular 
surface to replace the lost cartilage at the defective 
sites.15,22,28,31 Its rationale is based on the notion that 
autologous tissues rather than cells promote faster 
healing. However, multiple cylindrical grafts are 
required to fill the defect13; spaces between these 
grafts are filled with fibrocartilage and even new 
bone, possibly damaging both the opposite articular 
and treated surfaces. Large defects cannot be repaired 
because of limited donor osteochondral grafts. Donor-
site morbidity may be an issue because of the large 
amount of autologous tissue required.32
 Randomised controlled studies comparing ACT 
with other treatment modalities have shown mixed 
outcomes. ACT appears to produce better mid-
term results.13,22,28,31–36 Despite its success in treating 
cartilage defects, its use in developing countries is 
limited because tissue culture/transplant facilities 
are very costly.13,37–39 Cell-culture techniques with 
appropriate standards are difficult to master, and the 
transport and processing costs are unaffordable for 
the general public.11–13,32–6
 In our study, the biomechanical properties 
pertaining to the Brittberg/ICRS score and GAG 
quantification were not assessed. The biomechanical 
property (tensile strength and deformity resistance) 
of the repaired cartilage is best assessed using 
indentometry analysis. It must be comparable to 
normal cartilage so as not to disintegrate upon normal 
use or damage the opposite and adjacent articular 
surfaces. The ICRS histological scoring system10 was 
not used, as it is qualitative in nature and not subject 
to statistical analysis. The amount of type-II collagen 
was not quantified because specimens available for 
testing were limited. Larger animals should be used 
in future experiments to enable more diverse tests on 
repair outcomes and compare ACT to mosaicplasty, 
because only larger animals (e.g. goats or dogs) have 
sufficient amount of cartilage for mosaicplasty.34
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